76012
document
A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer . We randomized 122 premenopausal women to receive tamoxifen or to undergo a surgical oophorectomy . Of 54 evaluable women treated with tamoxifen , 24 % had an objective response , as compared with 21 % of 53 women having an oophorectomy . The median duration of response for tamoxifen ( 20 months ) was longer than that for surgical oophorectomy ( 7 months ) , but this did not achieve statistical significance ( P = .056 ) . Overall median survival was 15 months for 58 patients receiving tamoxifen and 25 months for 53 patients undergoing oophorectomy ( P = .18 ) . Toxicity was greater in those undergoing oophorectomy , though both treatments were well tolerated . In those premenopausal women for whom hormonal therapy is indicated , tamoxifen is a suitable alternative to surgical oophorectomy .
76013
Intervention_Pharmacological
tamoxifen
76014
Intervention_Surgical
surgical oophorectomy
76015
Intervention_Pharmacological
tamoxifen
76016
Intervention_Surgical
undergo a surgical oophorectomy .
76017
Intervention_Pharmacological
tamoxifen
76018
Intervention_Surgical
oophorectomy
76019
Intervention_Pharmacological
tamoxifen
76020
Intervention_Surgical
surgical oophorectomy
76021
Intervention_Pharmacological
tamoxifen
76022
Intervention_Surgical
surgical oophorectomy
76023
Outcome_Other
objective response
76024
Outcome_Other
median duration of response
76025
Outcome_Mortality
Overall median survival
76026
Outcome_Adverse-effects
Toxicity
76027
Outcome_Other
well tolerated .
76028
Participant_Condition
premenopausal patients with advanced breast cancer .
76029
Participant_Sample-size
122
76030
Participant_Condition
premenopausal
76031
Participant_Sex
women
76032
Participant_Sample-size
54
76033
Participant_Sex
women
76034
Participant_Sample-size
53
76035
Participant_Sex
women
76036
Participant_Sample-size
58
76037
Participant_Condition
premenopausal
76038
Participant_Sex
women